Latest from Callio

Callio Therapeutics appoints Zachary Hornby as Chief Executive Officer, with Piers Ingram, PhD, transitioning to Senior Advisor.

Trials in Progress poster at ASCO highlights the Phase 1 trial design of CLIO-8221.

At ASCO 2026, Callio Therapeutics will present a trials in progress poster on May 30, 2026, highlighting the Phase 1 trial design of CLIO-8221

CLIO-8221, a novel, first-in-class dual-payload antibody-drug conjugate targets HER2 to co-deliver Topo1i and ATRi payloads to overcome Topo1i resistance.

At AACR 2026, Callio Therapeutics will present preclinical data demonstrating that CLIO-8221 provides a wide therapeutic window with strong durable activity

Callio Therapeutics today announced that the first patient has been dosed in a Phase I clinical trial evaluating CLIO-8221 in patients with advanced HER2-expressing solid tumors